- Home
- EDU vs CORT Comparison
EDU vs CORT Comparison
Compare EDU & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDU
- CORT
- Stock Information
- Founded
- EDU 1993
- CORT 1998
- Country
- EDU China
- CORT United States
- Employees
- EDU N/A
- CORT N/A
- Industry
- EDU Other Consumer Services
- CORT Biotechnology: Pharmaceutical Preparations
- Sector
- EDU Real Estate
- CORT Health Care
- Exchange
- EDU Nasdaq
- CORT Nasdaq
- Market Cap
- EDU 8.8B
- CORT 7.6B
- IPO Year
- EDU 2006
- CORT N/A
- Fundamental
- Price
- EDU $54.22
- CORT $75.18
- Analyst Decision
- EDU Hold
- CORT Strong Buy
- Analyst Count
- EDU 5
- CORT 4
- Target Price
- EDU $56.60
- CORT $139.00
- AVG Volume (30 Days)
- EDU 808.2K
- CORT 675.5K
- Earning Date
- EDU 10-22-2025
- CORT 10-29-2025
- Dividend Yield
- EDU N/A
- CORT N/A
- EPS Growth
- EDU 27.50
- CORT N/A
- EPS
- EDU 2.29
- CORT 1.11
- Revenue
- EDU $4,900,262,000.00
- CORT $716,080,000.00
- Revenue This Year
- EDU $9.22
- CORT $30.62
- Revenue Next Year
- EDU $10.00
- CORT $37.68
- P/E Ratio
- EDU $23.02
- CORT $67.23
- Revenue Growth
- EDU 13.60
- CORT 25.71
- 52 Week Low
- EDU $40.66
- CORT $38.68
- 52 Week High
- EDU $87.26
- CORT $117.33
- Technical
- Relative Strength Index (RSI)
- EDU 68.11
- CORT 60.68
- Support Level
- EDU $52.37
- CORT $69.03
- Resistance Level
- EDU $55.34
- CORT $74.79
- Average True Range (ATR)
- EDU 1.23
- CORT 2.69
- MACD
- EDU 0.48
- CORT 0.32
- Stochastic Oscillator
- EDU 87.30
- CORT 95.68
About EDU New Oriental Education & Technology Group Inc.
New Oriental Education & Technology is a prominent private education provider in China, offering a wide array of educational services. These include overseas test preparation and consulting services, high school academic tutoring, nonacademic tutoring, and intelligent learning systems and devices. Additionally, the company holds a 57% ownership stake in East Buy, a leading player in the livestreaming e-commerce market.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.